A scoping review on the efficacy, effectiveness, and safety of different pharmacological therapies for the management of patients with glucocorticoid-induced osteoporosis
Revista Colombiana de Endocrinología, Diabetes & Metabolismo · 25.06.2026 · 13 (2)
DOI: 10.53853/encr.13.2.955 ↗Kurz gefasst
Scoping Review in der Zeitschrift Revista Colombiana de Endocrinología, Diabetes & Metabolismo, online erschienen am 25.06.2026. Verfasst von Gloria Ibis Tirado Romero und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Glucocorticoid-induced osteoporosis (GIOP) is a common secondary osteoporosis resulting from chronic corticosteroid use. It affects bone homeostasis, leading to significant reductions in bone mineral density (BMD) and an increased risk of vertebral and non-vertebral fractures. Due to the increasing number of patients requiring long-term glucocorticoid therapy, a comprehensive understanding of pharmacological interventions available for glucocorticoid-induced osteoporosis is essential.
Objective
To evaluate the efficacy, effectiveness, and safety of different pharmacological therapies used in the management of patients with glucocorticoid-induced osteoporosis through a scoping review of the available literature.
Methods
Following the Joanna Briggs Institute (JBI) methodology, a scoping review was conducted using major databases (PubMed, Embase, Cochrane, and others). Studies including adults with glucocorticoid-induced osteoporosis treated with pharmacological therapies such as bisphosphonates, denosumab, teriparatide, and others were considered. Outcomes focused on changes in bone mineral density, fracture risk reduction, and treatment safety. A total of 40 studies were included (37 on efficacy, 1 on effectiveness, and 12 on safety).
Results
Bisphosphonates (e.g., risedronate, alendronate, and zoledronate) significantly improved lumbar spine bone mineral density (up to +4.8%; with variability across studies, including mean changes around +4.9% ± 4.5% in randomized controlled trials [RCTs]) and reduced vertebral fracture risk (by up to 82.4%). Teriparatide demonstrated superior efficacy in increasing bone mineral density (+7.8% to +11.0%) and reducing fracture incidence, especially in high-risk patients. Denosumab also showed notable improvements in bone mineral density and bone turnover markers. Adverse events were generally mild, with gastrointestinal and flu-like symptoms being the most commonly reported.
Discussion
Bisphosphonates remain the first-line therapy for glucocorticoid-induced osteoporosis due to their efficacy and safety profile. Teriparatide may be preferable for high-risk patients or those with severe bone formation suppression. Denosumab is a valid alternative, particularly for patients who are intolerant to bisphosphonates. This review highlights the importance of individualized therapy based on fracture risk and comorbidities.
Zitieren
APA
Romero, G. I. T., Alvarado, J. F., Orduz, S. D. M., Rivera, S. K. G., & Flórez, Z. V. G. (2026). A scoping review on the efficacy, effectiveness, and safety of different pharmacological therapies for the management of patients with glucocorticoid-induced osteoporosis. Revista Colombiana de Endocrinología, Diabetes & Metabolismo, 13(2). https://doi.org/10.53853/encr.13.2.955
Vancouver
Romero GIT, Alvarado JF, Orduz SDM, Rivera SKG, Flórez ZVG. A scoping review on the efficacy, effectiveness, and safety of different pharmacological therapies for the management of patients with glucocorticoid-induced osteoporosis. Revista Colombiana de Endocrinología, Diabetes & Metabolismo. 2026;13(2). doi:10.53853/encr.13.2.955
BibTeX
@article{Romero2026,
author = {Romero, Gloria Ibis Tirado and Alvarado, Juan Felipe and Orduz, Stefany Daniela Mesa and Rivera, Syndi Katherine Guarín and Flórez, Zeyany Vanessa Guerrero},
title = {A scoping review on the efficacy, effectiveness, and safety of different pharmacological therapies for the management of patients with glucocorticoid-induced osteoporosis},
journal = {Revista Colombiana de Endocrinología, Diabetes & Metabolismo},
year = {2026},
volume = {13},
number = {2},
doi = {10.53853/encr.13.2.955}
}
EUVIMED